TherapeuticsMD (FRA:29TA) E10: €-16.52 (As of Mar. 2026)


FRA:29TA TherapeuticsMD Inc FRA:29TA
44 GF Score
Price €1.68
GF Value €1.75
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is TherapeuticsMD E10?

TherapeuticsMD FRA:29TA +1.82% 44 E10 is €-16.52 as of Mar. 2026. GuruFocus rates FRA:29TA with a GF Score™ of 44/100 and a GF Value™ of €1.75 (Fairly Valued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

TherapeuticsMD's adjusted earnings per share data for the three months ended in Mar. 2026 was €0.009. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-16.52 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was 7.30% per year. During the past 5 years, the average E10 Growth Rate was 15.70% per year. During the past 10 years, the average E10 Growth Rate was 30.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of TherapeuticsMD was 49.90% per year. The lowest was -36.00% per year. And the median was 6.45% per year.

As of today (2026-07-09), TherapeuticsMD's current stock price is €1.68. TherapeuticsMD's E10 for the quarter that ended in Mar. 2026 was €-16.52. TherapeuticsMD's Shiller PE Ratio of today is .


TherapeuticsMD  (FRA:29TA) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


TherapeuticsMD E10 Related Terms


TherapeuticsMD E10 Historical Data

* Premium members only.

The historical data trend for TherapeuticsMD's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TherapeuticsMD E10 Chart

TherapeuticsMD Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -21.39 -42.89 -104.00 -253.73 -16.33

TherapeuticsMD Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -229.78 -175.75 -184.12 -16.33 -16.52

FRA:29TA vs CPHI, RMTI, AYTU: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, TherapeuticsMD's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TherapeuticsMD Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TherapeuticsMD's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where TherapeuticsMD's Shiller PE Ratio falls into.


FRA:29TA
44GF Score
TherapeuticsMD Inc FRA:29TA
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TherapeuticsMD E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, TherapeuticsMD's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.009/330.2130*330.2130
=0.009

Current CPI (Mar. 2026) = 330.2130.

TherapeuticsMD Quarterly Data

per share eps CPI Adj_EPS
201606 -4.895 241.018 -6.707
201609 -5.791 241.428 -7.921
201612 -5.688 241.432 -7.780
201703 -5.142 243.801 -6.965
201706 -4.450 244.955 -5.999
201709 -2.937 246.819 -3.929
201712 -4.225 246.524 -5.659
201803 -4.460 249.554 -5.902
201806 -6.420 251.989 -8.413
201809 -6.856 252.439 -8.968
201812 -7.471 251.233 -9.820
201903 -7.080 254.202 -9.197
201906 -10.178 256.143 -13.121
201909 -5.902 256.759 -7.590
201912 -8.550 256.974 -10.987
202003 -9.502 258.115 -12.156
202006 -8.436 257.797 -10.806
202009 -5.094 260.280 -6.463
202012 -6.165 260.474 -7.816
202103 -4.763 264.877 -5.938
202106 -4.490 271.696 -5.457
202109 -4.777 274.310 -5.751
202112 -4.425 278.802 -5.241
202203 -5.176 287.504 -5.945
202206 12.137 296.311 13.526
202209 -3.161 296.808 -3.517
202212 7.646 296.797 8.507
202303 -0.346 301.836 -0.379
202306 -0.222 305.109 -0.240
202309 -0.300 307.789 -0.322
202312 -0.055 306.746 -0.059
202403 -0.055 312.332 -0.058
202406 -0.084 314.175 -0.088
202409 -0.045 315.301 -0.047
202412 0.019 315.605 0.020
202503 -0.055 319.799 -0.057
202506 0.043 322.561 0.044
202509 0.009 324.800 0.009
202512 -0.043 324.054 -0.044
202603 0.009 330.213 0.009

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-16.52 mean?
TherapeuticsMD (FRA:29TA) has a E10 of €-16.52 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on TherapeuticsMD and its competitors.
Is TherapeuticsMD's E10 too high?
TherapeuticsMD's current E10 is €-16.52. Overall, TherapeuticsMD has a GF Score™ of 44/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TherapeuticsMD's E10 compare to CPHI and RMTI?
TherapeuticsMD's E10 of €-16.52 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on TherapeuticsMD and its competitors. TherapeuticsMD's current E10 is €-16.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TherapeuticsMD stock overvalued right now?
Based on GuruFocus' analysis, TherapeuticsMD (FRA:29TA) is currently considered Fairly Valued. The stock's GF Value™ is €1.75, compared to a current price of €1.68 — trading 4% below its estimated fair value. The current E10 is €-16.52. TherapeuticsMD's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For TherapeuticsMD (FRA:29TA), the current E10 is €-16.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TherapeuticsMD (FRA:29TA) Overvalued in 2026?

Based on GuruFocus' analysis, TherapeuticsMD stock appears to be undervalued. The current stock price of €1.68 is trading 4% below its estimated GF Value™ of €1.75. GuruFocus considers TherapeuticsMD to be Fairly Valued.

Key valuation signals for FRA:29TA:

  • E10: €-16.52
  • GF Value™: €1.75 vs. price of €1.68 (4% below fair value)
  • GF Score™: 44/100 with 3 warning signs

No single metric tells the full story. See the FRA:29TA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TherapeuticsMD Business Description

Other Exchanges TXMD:USA
Address 951 Yamato Road, Suite 220, Boca Raton, FL, USA, 33431
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.
44GF Score

Get the complete analysis for FRA:29TA

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.68
Price
€1.75
GF Value